CA: A Cancer Journal for Clinicians最新文献

{"title":"Screening for colorectal cancer.","authors":"","doi":"10.3322/caac.70087","DOIUrl":"10.3322/caac.70087","url":null,"abstract":"","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 3","pages":"e70087"},"PeriodicalIF":685.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148025209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Twenty-year results of the randomized European Organization for Research and Treatment of Cancer trial 22922/10925 evaluating internal mammary chain and medial supraclavicular lymph node irradiation in stage I-III breast cancer.","authors":"Orit Kaidar-Person, Caroline G Weltens, Catherine Fortpied, Luc J E E Scheijmans, Carine Y Kirkove, Volker Budach, Karine Peignaux-Casasnovas, Mariacarla Valli, Max Peters, Femke van der Leij, Sofia Rivera, Nicola Weidner, Desirée H J G van den Bongard, Claudia Linsenmeier, Roxolyana Abdah-Bortnyak, Shaymaa Hosni, Eveline Koiter, Antoine M Engelen, Adinda Baten, Lydia Champezou, Alain Fourquet, Harry G M M Bartelink, Henk Struikmans, Philip M P Poortmans","doi":"10.3322/caac.70082","DOIUrl":"10.3322/caac.70082","url":null,"abstract":"<p><p>European Organization for Research and Treatment of Cancer trial EORTC 22922/10925 evaluated internal mammary and medial supraclavicular (IM-MS) lymph node irradiation (IM-MS-RT) in patients with stage I-III breast cancer. Eligible patients had involved axillary nodes and/or centrally/medially located tumors regardless of nodal involvement. The primary end point was overall survival, secondary end points were disease-free survival, distant metastases-free survival, breast cancer mortality, and any breast recurrence. Between 1996 and 2004, 4004 patients were randomized. The median patient age was 54 years. At a median follow-up of 22.2 years, 1550 (38.7%) patients died, of whom 796 (51.4%) died from breast cancer. At 20 years, the overall survival rate was 61.8% in the control group versus 61.0% in the IM-MS-RT group (hazard ratio [HR], 1.00; p = .967); the disease-free survival rate was 49.0% versus 48.2%, respectively (HR, 0.97; p = .515); and the distant metastases-free survival rate was 59.8% versus 58.9%, respectively (HR, 0.97; p = .578). The breast cancer mortality rate was 22.4% in the control group and 18.6% in the IM-MS-RT group (HR, 0.82; p = .006), whereas the rate of deaths not from breast cancer or from unknown causes was 15.8% versus 20.4%, respectively (HR, 1.26; p = .002). Lung fibrosis, cardiac fibrosis, and cardiac diseases were more frequent after IM-MS-RT versus no IM-MS-RT (6.3% vs. 3.2%, 2.7% vs. 1.7%. and 15.2% vs. 11.7%, respectively); and the rates of severe cardiac and lung morbidities (scores of 3 or 4) were 1.9% versus 1.7% and 0.3% versus 0.0%, respectively. Breast cancer mortality at 20 years was statistically significantly lower after IM-MS-RT, but deaths not from breast cancer increased after 15 years, resulting in no long-term benefit of IM-MS-RT on overall survival. Therefore, the authors strongly call for very long-term follow-up of treatments for prognostically favorable cancers such as breast cancer.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 3","pages":"e70082"},"PeriodicalIF":685.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13179593/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147959518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medullary thyroid carcinoma and RET molecular testing: A virtual tumor board on clinical decision-making.","authors":"Lucas Kallas-Silva, Victor Alexandre Dos Santos Valsecchi, Ana O Hoff, Evelin Cavalcante Farias, Rui Monteiro de Barros Maciel, Rachel Riera, Laura Sterian Ward, Lucas Leite Cunha","doi":"10.3322/caac.70086","DOIUrl":"10.3322/caac.70086","url":null,"abstract":"","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 3","pages":"e70086"},"PeriodicalIF":685.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13161516/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147872512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Colorectal cancer screening: An update to the American Cancer Society guideline, 2026.","authors":"Andrew M D Wolf, Richard M Hoffman, Louise C Walter, Charnita Zeigler-Johnson, Timothy R Church, Carmen E Guerra, Elena B Elkin, Ruth Etzioni, Abbe Herzig, Kevin C Oeffinger, Rebecca B Perkins, Sana Raoof, Ya-Chen Tina Shih, Steven J Skates, Tyler B Kratzer, Deana Manassaram-Baptiste, Robert A Smith","doi":"10.3322/caac.70083","DOIUrl":"10.3322/caac.70083","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is a leading cause of cancer incidence and mortality in the United States, with rates recently increasing among adults younger than 65 years. In 2018, the American Cancer Society (ACS) lowered the recommended age to initiate screening for average-risk adults to age 45 years. Since then, new molecular-based screening tests-a multitarget stool RNA test (mt-sRNA), a next-generation mt-sDNA test, and a blood-based cell-free DNA assay-have received regulatory approval for CRC screening. For this update, the ACS Guideline Development Group commissioned a targeted, systematic evidence review evaluating diagnostic performance and published modeling studies to judge the potential impact of these tests on CRC incidence and mortality. The ACS reaffirms the recommendation that average-risk adults should initiate CRC screening at age 45 years and continue through age 75 years for those with a life expectancy greater than 10 years. Consistent with prior guidelines, the ACS emphasizes that offering multiple, recommended screening options supports informed patient choice and may improve participation, because the most effective screening test is the one that the patient completes. The next-generation mt-sDNA test, which is an updated version of an already recommended mt-sDNA test, and the mt-sRNA test demonstrated high sensitivity for CRC and moderate sensitivity for advanced precancerous lesions and are recommended, along with annual high-sensitivity fecal immunochemical and high-sensitivity guaiac-based fecal occult blood tests, as preferred stool-based screening options at 3-year intervals. Compared with established stool-based tests, blood-based tests demonstrated lower sensitivity for both advanced precancerous lesions and stage I cancers, with modeling studies predicting less effectiveness in reducing CRC incidence and mortality. At this time, blood-based tests should be recommended only to individuals who decline or do not complete preferred screening tests. Ongoing evaluation of adherence, real-world implementation, and clinical outcomes will inform future updates for these new tests. For screening to be effective, a positive result on any noncolonoscopy screening test requires timely follow-up with colonoscopy, preferably within 6 months, to complete the screening process.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 3","pages":"e70083"},"PeriodicalIF":685.2,"publicationDate":"2026-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148025243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Adding carboplatin to sequential taxane–anthracycline neoadjuvant chemotherapy shows improved event-free and overall survival benefits in premenopausal women with triple-negative breast cancer","authors":"Carrie Printz","doi":"10.3322/caac.70077","DOIUrl":"10.3322/caac.70077","url":null,"abstract":"&lt;p&gt;The standard treatment for patients with nonmetastatic triple-negative breast cancer (TNBC) is surgery, chemotherapy, and radiotherapy. The immune checkpoint inhibitors pembrolizumab and durvalumab have led to improvements in event-free survival (EFS)—and also overall survival (OS) in the case of pembrolizumab—when added to treatment regimens of anthracycline, cyclophosphamide, taxane, and a platinum agent as part of neoadjuvant therapy. Still, clinicians have continued to debate the benefits of including platinum in multidrug adjuvant/neoadjuvant regimens because initial reports from several randomized trials failed to show added benefit.&lt;/p&gt;&lt;p&gt;For these reasons, researchers conducted a new randomized, phase 3 clinical trial—the Tata Memorial Centre (TMC) study—to glean more definitive evidence about the benefits of adding carboplatin to sequential taxane–anthracycline neoadjuvant chemotherapy.&lt;/p&gt;&lt;p&gt;The randomized, open-label trial was conducted at a single tertiary cancer center in India, with the findings published in the &lt;i&gt;Journal of Clinical Oncology&lt;/i&gt; (doi:10.1200/JCO-25-01023). The study demonstrated that, in the overall trial population, carboplatin showed a trend for increased EFS that did not reach significance, but the drug was associated with statistically significantly improved OS. In a subset analysis, in premenopausal patients, both EFS and OS improved significantly, whereas there were no improvements in these outcomes in the postmenopausal population. This trial was the first one to use a menopause-status subanalysis of the benefits of adding carboplatin.&lt;/p&gt;&lt;p&gt;Patients were stratified by clinical stage, including large operable or locally advanced tumors, and by menopausal status. They were randomized in a 1:1 ratio to receive either carboplatin or no carboplatin as part of neoadjuvant chemotherapy.&lt;/p&gt;&lt;p&gt;The control arm (356 patients) received neoadjuvant chemotherapy with paclitaxel at a dose of 100 mg/m&lt;sup&gt;2&lt;/sup&gt; as a 1-h infusion once per week for 8 weeks; this was followed by an anthracycline regimen (doxorubicin at 60 mg/m&lt;sup&gt;2&lt;/sup&gt; or epirubicin at 90 mg/m&lt;sup&gt;2&lt;/sup&gt; plus cyclophosphamide at 600 mg/m&lt;sup&gt;2&lt;/sup&gt;) once every 3 weeks for four cycles.&lt;/p&gt;&lt;p&gt;In the platinum arm, 361 patients received carboplatin at a dose of AUC-2 with paclitaxel once per week for 8 weeks. Immune checkpoint inhibitors and capecitabine were not routinely used as part of the treatment regimen.&lt;/p&gt;&lt;p&gt;The primary endpoint was EFS, which was the time interval between random assignment and disease progression, relapse, or death due to any cause. OS was a secondary endpoint and was defined as the time interval between random assignment and death due to any cause.&lt;/p&gt;&lt;p&gt;Another secondary endpoint was pathologic complete response (pCR) to neoadjuvant chemotherapy, which was defined as the absence of invasive cancer within the breast and regional lymph nodes. Toxicity was also a secondary endpoint in the study.&lt;/p&gt;&lt;p&gt;Of the 720 patients rand","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70077","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147721239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Radiotherapy followed by adjuvant temozolomide improves survival for patients with aggressive IDH-mutated anaplastic glioma","authors":"Carrie Printz","doi":"10.3322/caac.70078","DOIUrl":"10.3322/caac.70078","url":null,"abstract":"&lt;p&gt;An anaplastic astrocytoma is a grade 3 glioma that develops from glial cells supporting nerve cells. It accounts for 2% of brain tumors and is more common among people in their 30s to 50s. Standard treatment includes surgery and radiation, with chemotherapy given during or after radiation.&lt;/p&gt;&lt;p&gt;Isocitrate dehydrogenase–mutated (&lt;i&gt;IDHmt&lt;/i&gt;) tumors, first identified in 2008, are key oncogenic drivers in the majority of astrocytomas and are associated with a better disease prognosis. However, researchers had not been certain if adding temozolomide chemotherapy during and after radiotherapy for grade 3 &lt;i&gt;IDHmt&lt;/i&gt; astrocytoma would improve survival.&lt;/p&gt;&lt;p&gt;The randomized, open-label, phase 3 CATNON study was conducted between 2007 and 2015. A total of 751 newly diagnosed participants aged 18 years or older, including 444 who were diagnosed with an &lt;i&gt;IDHmt&lt;/i&gt; tumor, were evaluated.&lt;/p&gt;&lt;p&gt;At a median follow-up for OS of 10.9 years, participants treated with adjuvant temozolomide after radiotherapy showed improved OS in comparison with those not treated with adjuvant temozolomide (hazard ratio [HR], 0.65; 95% CI, 0.54–0.77). Concurrent temozolomide did not show improved OS in comparison with no concurrent temozolomide (HR, 0.91; 95% CI, 0.76–1.08). In an analysis of patients with an &lt;i&gt;IDHmt&lt;/i&gt; tumor, concurrent temozolomide did not have a statistically significant effect on OS (median, 7–9 years [8.2–12.5 years] vs. 2–7 years [6.2–9.4 years]; HR, 0.81; 95% CI, 0.63–1.04).&lt;/p&gt;&lt;p&gt;For &lt;i&gt;IDHmt&lt;/i&gt; patients treated with adjuvant temozolomide, the median OS was 12.5 years (95% CI, 9.4–15.0 years) versus 6.0 years (95% CI, 5.1–7.2 years) for those not treated with adjuvant temozolomide (HR, 0.54; 95% CI, 0.42–0.69). In patients with &lt;i&gt;IDH&lt;/i&gt; wild-type tumors, no benefit was found from treatment with either concurrent or adjuvant temozolomide.&lt;/p&gt;&lt;p&gt;The study also found that several DNA alterations were associated with poorer outcomes and did not predict a benefit from temozolomide. These included &lt;i&gt;PDGFRA&lt;/i&gt; and &lt;i&gt;CDK4&lt;/i&gt;, homozygous deletion of &lt;i&gt;CDKN2A&lt;/i&gt;, and total copy number variation.&lt;/p&gt;&lt;p&gt;Patrick Wen, MD, director of the Center for Neuro-Oncology at the Dana–Farber Cancer Institute in Boston, Massachusetts, praises the study for providing additional information. It confirms findings from the previous interim analysis, which established 12 months of temozolomide after radiation as the standard of care, he notes.&lt;/p&gt;&lt;p&gt;“The study had a complicated design, but it answered a lot of questions that were useful to the field,” he says. “It was also striking that the subgroup of &lt;i&gt;IDH&lt;/i&gt;-wild type, also known as molecular glioblastoma, did not respond to chemotherapy. That is a concerning and important finding.”&lt;/p&gt;&lt;p&gt;Dr Wen adds that researchers are working to find other therapies that may further benefit patients undergoing radiotherapy and temozolomide treatment. This research includes a phase 3 Alliance for Clinical Trials in Oncology s","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70078","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147721248","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Nonpharmacologic interventions for managing distress, anxiety, and depression for patients with cancer and their family caregivers: A systematic review and meta-analysis","authors":"Lisa C. Schiess MSc, PhD candidate,&nbsp;Lixin L. Song PhD, RN,&nbsp;Sabine Schädelin Msc,&nbsp;Thomas Fürst PhD,&nbsp;Corinne Urech PhD,&nbsp;Christopher R. Friese PhD, RN, AOCN,&nbsp;Maria C. Katapodi PhD, RN","doi":"10.3322/caac.70076","DOIUrl":"10.3322/caac.70076","url":null,"abstract":"<p>As more cancer treatments take place in outpatient settings, family caregivers provide essential care and emotional support over long periods. Unaddressed patient and caregiver psychological distress can lead to worse outcomes, reflecting the challenges of managing complex care demands in the home setting. This systematic review and meta-analysis examined how well nonpharmacologic interventions (NPIs) reduce distress, anxiety, and depression in adult patients with solid tumors and their family caregivers. The authors included 68 randomized controlled trials (RCTs) with a total of 11,987 participants. NPIs were characterized as psychoeducation, therapeutic counseling, skills training, or behavior modification. By using random-effects models (Hedges g), they observed that NPIs significantly reduced patient distress at both 0.0–3.0 months (g = 0.13) and 3.1–6.0 months (g = 0.18), but NPIs did not significantly reduce caregiver distress. In the short term (0.0–3.0 months), NPIs also significantly reduced anxiety (g = 0.31 for patients; g = 0.15 for caregivers) and depression (g = 0.28 for patients; g = 0.25 for caregivers). Subgroup analyses examined the impact of patient and caregiver characteristics along with NPI type, delivery format, dose, and duration. NPIs delivered jointly to patients and caregivers yielded significant effects that were higher compared with NPIs delivered separately. NPIs can help manage distress in patients and reduce anxiety and depression in both patients and caregivers. However, the lack of long-term follow-up limits our understanding of their impact on patients and caregivers with prolonged or delayed psychological symptoms (PROSPERO registration number CRD42024536629).</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70076","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147681554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating multimodal management and molecular profiling in a patient with BRAF V600E–positive melanoma and brain metastases","authors":"David Gritsch MD, PhD,&nbsp;Riley M. Fadden CNP,&nbsp;Maura K. Mahar CNP,&nbsp;Melin J. Khandsekar MD, PhD,&nbsp;Kevin S. Oh MD. MBA,&nbsp;Daniel P. Cahil III MD, PhD,&nbsp;Gavin P. Dunn MD, PhD,&nbsp;Ryan J. Sullivan MD,&nbsp;Priscilla K. Brastianos MD","doi":"10.3322/caac.70079","DOIUrl":"10.3322/caac.70079","url":null,"abstract":"&lt;p&gt;A man in his late 20s was diagnosed with &lt;i&gt;BRAF V600E&lt;/i&gt;-mutated cutaneous melanoma of the left knee (T3a) and underwent wide local excision. One year later, he had a solitary local recurrence resected and received 12 months of adjuvant dabrafenib and trametinib. Seven months after completion of adjuvant therapy, he developed headaches and a right visual field deficit. Magnetic resonance imaging (MRI) revealed a solitary left occipital enhancing lesion. Subtotal resection confirmed melanoma brain metastasis (MBM), and he initiated adjuvant ipilimumab/nivolumab, complicated by &lt;i&gt;Clostridiodies difficile&lt;/i&gt; colitis and subsequent immune-related colitis requiring corticosteroids and vedolizumab. Postoperative radiotherapy (RT) was completed. Six months later, he underwent stereotactic radiosurgery (SRS) to a new left putamen lesion (hereinafter referred to as &lt;i&gt;basal ganglia lesion&lt;/i&gt;). Nivolumab was resumed but discontinued because of severe inflammatory arthritis requiring immunosuppression.&lt;/p&gt;&lt;p&gt;The patient presented to our institution 6 months later. Positron emission tomography/computed tomography identified a new right thigh metastasis. MRI revealed apparent enlargement of the left occipital and basal ganglia lesions (Figure 1). Ipilimumab/nivolumab treatment was reinitiated but was complicated 3 months later by worsening right hemiparesis and hemianopia in the setting of hemorrhagic changes in both lesions. Stereotactic biopsy of the occipital lesion confirmed radiation necrosis. He subsequently developed acute worsening of right hemiparesis, and a lacunar infarct, attributed to mass effect on the lenticulostriate vessels, was identified. Given his biopsy-proven radiation necrosis and complete response of the right thigh metastasis, with no other systemic disease identified at the time, immunotherapy was discontinued (the last dose was received 3–4 weeks before biopsy).&lt;/p&gt;&lt;p&gt;Three months after the biopsy, resection of the enlarging occipital lesion was performed in the setting of worsening hemianopia and again confirmed radiation necrosis. One month later, the basal ganglia lesion showed further hemorrhagic progression and enlarging nodular enhancement with worsening edema, headaches, and aphasia. Surgical re-resection was not recommended. Multidisciplinary review concluded that, although radiation necrosis could not be excluded, a focal nodular region of enhancement raised concern for active tumor progression. Given diagnostic uncertainty and the need for rapid intracranial disease control, the team initiated encorafenib/binimetinib as the systemic therapy most likely to produce a prompt response and help distinguish tumor progression from radiation necrosis. Imaging 4 weeks later revealed reduced lesion size and edema. Over the following months, he was doing well clinically with only mild symptom burden and was able to work full time. After 7 months on targeted therapy, MRI revealed asymptomatic progression in the basal ganglia a","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70079","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147518896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correction to “American Cancer Society’s report on the status of cancer disparities in the United States, 2025”","authors":"","doi":"10.3322/caac.70080","DOIUrl":"10.3322/caac.70080","url":null,"abstract":"<p>Islami F, Arias G, Lee D, et al. American Cancer Society’s Report on the Status of Cancer Disparities in the United States, 2025. <i>CA Cancer J Clin</i>. 2026;e70045. doi:10.3322/caac.70045</p><p>The data source for cancer survival data in the footnotes for Figure 3 and supplementary Figure S3 should be corrected to “Source: Surveillance, Epidemiology, and End Results 21 registries (excluding Illinois).” The published version was incorrectly listed as “Source: North American Association of Central Cancer Registries (estimates by race and ethnicity) and Surveillance, Epidemiology, and End Results 21 registries (excluding Illinois; estimates by urbanicity of county of residence).”</p><p>We apologize for this error.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13004426/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147490239","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aumolertinib with carboplatin–pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study","authors":"Jian-Chun Duan MD,&nbsp;Jia Zhong MD,&nbsp;Bo-Yang Sun MD,&nbsp;Wen-Hua Zhao MD,&nbsp;Lin Wu MD,&nbsp;Kai-Lun Fei MD,&nbsp;Qian Chu MD,&nbsp;Qi-Sen Guo MM,&nbsp;Qi-Bin Song MD,&nbsp;Yan Yu MD,&nbsp;Da-Xing Zhu MD,&nbsp;Xin-Yan Liu MD,&nbsp;Jun Zhao MD,&nbsp;Zhi-Xiang Zhan MB,&nbsp;Shi Li MB,&nbsp;Lei Nie MB,&nbsp;Jie Lin MM,&nbsp;Xiao-Dong Peng MD,&nbsp;Dian-Sheng Zhong MD,&nbsp;Jin Zhou MD,&nbsp;Li-Hua Li MD,&nbsp;Yun-Fang Chen MB,&nbsp;Chen Hu PhD,&nbsp;Tony Mok MD,&nbsp;Zhi-Jie Wang MD,&nbsp;Jie Wang MD","doi":"10.3322/caac.70071","DOIUrl":"10.3322/caac.70071","url":null,"abstract":"<p>Third-generation epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR-TKIs) are standard first-line therapy for advanced, <i>EGFR</i>-mutated nonsmall cell lung cancer (NSCLC). However, their benefit is limited in patients who have co-existing tumor suppressor gene (TSG) mutations, highlighting a need for intensified strategies to improve outcomes. ACROSS2 (ClinicalTrials.gov identifier NCT04500717) is the first prospective, multicenter, randomized phase 3 study to compare the third-generation EGFR-TKI aumolertinib in combination with carboplatin–pemetrexed versus aumolertinib monotherapy in patients who had NSCLC with <i>EGFR</i> mutations and concomitant TSG mutations. In total, 126 patients were enrolled and randomly assigned to either combination therapy (<i>n</i> = 62) or monotherapy (<i>n</i> = 64). The primary end point was median progression-free survival (PFS). At a median follow-up of 25.3 months, combination therapy significantly prolonged median PFS compared with monotherapy (19.78 vs 16.53 months; hazard ratio, 0.58; 95% confidence interval, 0.34–0.97). Landmark PFS rates at 12, 18, and 24 months were 78.7% versus 65.3%, 67.2% versus 40.8%, and 41.0% versus 29.9%, respectively. Subgroup analyses demonstrated a clear PFS benefit in patients who had co-existing tumor protein p53 (<i>TP53</i>) mutations. Grade 3 or greater adverse events occurred in 25.9% of patients who received combination therapy versus 17.2% of those who received monotherapy; no drug-related deaths were observed. Overall survival data were immature (data maturity, 4%). The ACROSS2 trial provides the first prospective evidence supporting a genotype-directed, chemotherapy-targeted intensification approach favoring aumolertinib plus carboplatin–pemetrexed for this molecularly defined population.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"76 2","pages":""},"PeriodicalIF":232.4,"publicationDate":"2026-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://acsjournals.onlinelibrary.wiley.com/doi/epdf/10.3322/caac.70071","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147439895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}